TLX (Telix Pharmaceuticals) Research & Development: $171.2 Mil (TTM As of Dec. 2025)


TLX Telix Pharmaceuticals Ltd TLX
50 GF Score
Price $10.86
GF Value $27.71
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Telix Pharmaceuticals Research & Development?

Telix Pharmaceuticals TLX +6.37% 50 Research & Development is $171.2 Mil as of Dec. 2025. GuruFocus rates TLX with a GF Score™ of 50/100 and a GF Value™ of $27.71 (Possible Value Trap). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Telix Pharmaceuticals's Research & Development for the six months ended in Dec. 2025 was $89.7 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $171.2 Mil.

Telix Pharmaceuticals  (NAS:TLX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Telix Pharmaceuticals Research & Development Related Terms

Telix Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Telix Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telix Pharmaceuticals Research & Development Chart

Telix Pharmaceuticals Annual Data
Trend Sep00 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.75 54.89 85.32 127.93 171.25

Telix Pharmaceuticals Semi-Annual Data
Sep00 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.16 55.44 72.49 81.58 89.67
TLX
50GF Score
Telix Pharmaceuticals Ltd TLX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Telix Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $171.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $171.2 Mil mean?
Telix Pharmaceuticals (TLX) has a Research & Development of $171.2 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Telix Pharmaceuticals and its competitors.
Is Telix Pharmaceuticals' Research & Development too high?
Telix Pharmaceuticals' current Research & Development is $171.2 Mil. Overall, Telix Pharmaceuticals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' Research & Development compare to VRTX and REGN?
Telix Pharmaceuticals' Research & Development of $171.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Telix Pharmaceuticals and its competitors. Telix Pharmaceuticals's current Research & Development is $171.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (TLX) is currently considered Possible Value Trap. The stock's GF Value™ is $27.71, compared to a current price of $10.86 — trading 60.8% below its estimated fair value. The current Research & Development is $171.2 Mil. Telix Pharmaceuticals' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Telix Pharmaceuticals (TLX), the current Research & Development is $171.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Telix Pharmaceuticals (TLX) Overvalued in 2026?

Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued. The current stock price of $10.86 is trading 60.8% below its estimated GF Value™ of $27.71. GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TLX:

  • Research & Development: $171.2 Mil
  • GF Value™: $27.71 vs. price of $10.86 (60.8% below fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Telix Pharmaceuticals Business Description

Address 55 Flemington Road, Level 4, North Melbourne, Melbourne, VIC, AUS, 3051
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
50GF Score

Get the complete analysis for TLX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.86
Price
$27.71
GF Value